Meeting
2022 ASCO Genitourinary Cancers Symposium
ARTO trial-(NCT03449719): Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing I line treatment with abiraterone acetate.
Authors
Giulio Francolini
Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
Giulio Francolini , Beatrice Detti , Vanessa Di Cataldo , Saverio Caini , Anna Rita Alitto , Silvana Parisi , Chiara Demofonti , Alessio Bruni , Gianluca Ingrosso , Giorgia Timon , Andrea Allegra , Michele Aquilano , Lucia Pia Ciccone , Viola Salvestrini , Giulio Frosini , Cecilia Cerbai , Isacco Desideri , Icro Meattini , Monica Mangoni , Lorenzo Livi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03449719
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 100)
DOI
10.1200/JCO.2022.40.6_suppl.100
Abstract #
100
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.
First Author: Giulio Francolini
Poster
2024 ASCO Genitourinary Cancers Symposium
Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN).
First Author: Giulio Francolini
Poster
2024 ASCO Genitourinary Cancers Symposium
ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer.
First Author: Giulio Francolini
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz